Biotechnology
Health
Therapy

Seres Therapeutics

$3.97
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.13 (-3.17%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell MCRB and other stocks, options, ETFs, and crypto commission-free!

About

Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. Read More It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Employees
145
Headquarters
Cambridge, Massachusetts
Founded
2010
Market Cap
163.15M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
188.30K
High Today
$4.24
Low Today
$3.95
Open Price
$4.13
Volume
40.51K
52 Week High
$9.75
52 Week Low
$3.94

Collections

Biotechnology
Health
Therapy
Technology
2015 IPO
US

News

Yahoo FinanceMay 4

Edited Transcript of MCRB earnings conference call or presentation 2-May-19 12:30pm GMT

Q1 2019 Seres Therapeutics Inc Earnings Call Cambridge May 4, 2019 (Thomson StreetEvents) -- Edited Transcript of Seres Therapeutics Inc earnings conference call or presentation Thursday, May 2, 2019 at 12:30:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Carlo Tanzi Seres Therapeutics, Inc. - VP of IR & Corporate Communication...

98
Yahoo FinanceMay 2

Seres Therapeutics, Inc. to Host Earnings Call

89
Yahoo FinanceMay 2

Seres Therapeutics (MCRB) Reports Q1 Loss, Lags Revenue Estimates

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

89

Earnings

-$0.76
-$0.37
$0.02
$0.41
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.38 per share
Actual
-$0.59 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.